Сальважная лимфаденэктомия у пациентов с рецидивом рака предстательной жедезы после радикальной простатэктомии

Отдельную группу больных, перенесших радикальную простатэктомию, составляют пациенты с изолированным рецидивом рака в лимфатических узлах, ограниченных регионарными и / или забрюшинными лимфатическими узлами. В качестве одного из вариантов лечения данной группы пациентов может быть применена лимфаденэктомия открытым или лапароскопическим (робот-ассистированным) доступами. Проведенный анализ литературных источников указывает на увеличение общей выживаемости данной группы пациентов при проведении лимфаденэктомии. Доступные методы визуализации, такие как мультипараметрическая магнитно-резонансная томография и позитронно-эмиссионная томография, позволяют более точно идентифицировать поражение лимфатических узлов у пациентов с биохимическим рецидивом рака простаты после радикальной простатэктомии. 

1. Abdollah F., Briganti A., Montorsi F. et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol 2015;67(5):839–49. DOI: 10.1016/j.eururo.2014.03.019. PMID: 24698524.

2. Mottet N., Bellmunt J., Briers E. et al. Netherlands: European Association of Urology, 2017. 146 р.

3. Giovacchini G., Picchio M., GraciaParra R. et al. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy. J Nucl Med 2014;55(2): 233–41. DOI: 10.2967/jnumed.113.123380. PMID: 24408897.

4. Suardi N., Porter C.R., Reuther A.M. et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112(6):1254–63. DOI: 10.1002/cncr.23293. PMID: 18286530.

5. de Jong I.J., Pruim P., Elsinga W. et al. C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44(1):32–9. PMID: 12814672.

6. Giovacchini G., Picchio M., Briganti A. et al. 11C-choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010;184(3):938–43. DOI: 10.1016/j.juro.2010.04.084. PMID: 20643445.

7. Krause B.J., Souvatzoglou M., Tuncel M. et al. The detection rate of 11C-cholinePET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35(1):18–23. DOI: 10.1007/s00259-007-0581-4. PMID: 17891394.

8. Heesakkers R.A., Hovels A.M., Jager G.J. et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9(9):850–6. DOI: 10.1016/S1470-2045(08)70203-1. PMID: 18708295.

9. Lecouvet F.E., El Mouedden J., Collette L. et al. Can whole-body magnetic resonance imaging with diffusionweighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012;62(1):68–75. DOI: 10.1016/j.eururo.2012.02.020. PMID: 22366187.

10. Harisinghani M.G., Barentsz J., Hahn P.F. et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Engl J Med 2003;348(25):2491–9. DOI: 10.1056/NEJMoa022749. PMID: 12815134.

11. Wang L., Hricak H., Kattan M.W. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006;186(3):743–8. DOI: 10.2214/AJR.04.1682. PMID: 16498101.

12. Schilling D., Schlemmer H.P., Wagner P.H. et al. Histological verification of 11Ccholine-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008;102(4):446–51. DOI: 10.1111/j.1464-410X.2008.07592.x. PMID: 18410442.

13. Winter A., Uphoff J., Henke R.P., Wawroschek F. First results of 11Ccholine PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010;84(4):418–23. PMID: 20299773. DOI: 10.1159/000296298.

14. Rinnab L., Mottaghy F.M., Simon J. 11C-Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: preliminary results of a prospective study. Urol Int 2008;81(2): 191–7. DOI: 10.1159/000144059. PMID: 18758218.

15. Castellucci P., Fuccio C., Rubello D. et al. Is there a role for 11C-choline PET/ CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase < 1.5 ng/ml? Eur J Nucl Med Mol Imaging 2011;38(1):55–63. DOI: 10.1007/s00259-010-1604-0. PMID: 20848281.

16. Mamede M., Ceci F., Castellucci P. et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level < 0.5 ng/ mL. Clin Nucl Med 2013;38(9):e342–5. DOI: 10.1097/RLU.0b013e31829af913. PMID: 23797218.

17. Tilki D., Reich O., Graser A. et al. 18FFluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013;63(5):792–6. DOI: 10.1016/j.eururo.2012.08.003. PMID: 22902037.

18. Rigatti P., Suardi N., Briganti A. et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by 11C-choline positron emission tomography/computed tomography. Eur Urol 2011;60:935–43. DOI: 10.1016/j.eururo.2011.07.060.

19. Jilg C.A., Rischke H.C., Reske S.N. et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012;188(6):2190–7. DOI: 10.1016/j.juro.2012.08.041. PMID: 23083862.

20. Suardi N., Karnes J., Joniau S. et al. Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases. J Urol 2013;189:317–8.

21. Suardi N., Gandaglia G., Gallina A. et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 2015;67(2):299–309. DOI: 10.1016/j.eururo.2014.02.011. PMID: 24571959.

22. Coelho R.F., Palmer K.J., Moniz R.R. et al. Early complication rates in a singlesurgeon series of 2500 robotic-assisted radical prostatectomies: report applying a standardized grading system. Eur Urol 2010;57(6):945–52. DOI: 10.1016/j.eururo.2010.02.001. PMID: 20181424.